Novartis Licenses Mesoblast’s Stem Cell Therapy Remestemcel-L
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 11 (Table of Contents)
Published: 24 Nov-2020
DOI: 10.3833/pdr.v2020.i11.2571 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its cell therapy pipeline, Novartis has entered into a worldwide license and collaboration agreement with Mesoblast to develop, commercialise and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome, including that associated with COVID-19...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS